Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company’s web site at www.oncothyreon.com.
- 17 years ago
QualityStocks
Oncothyreon, Inc. (NASDAQ: ONTY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven Breast Cancer Imaging
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled…
-
QualityStocksNewsBreaks – Forward Industries, Inc. (NASDAQ: FORD) Featured in Oak Ridge Financial Research Report Highlighting Transition to Solana Digital Asset Treasury Model
Forward Industries (NASDAQ: FORD) has been featured in a new research report by Oak Ridge…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell…